Loading...

Palatin Technologies

DB:PTNA
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PTNA
DB
$215M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The last earnings update was 67 days ago. More info.


Add to Portfolio Compare Print
  • Palatin Technologies has significant price volatility in the past 3 months.
PTNA Share Price and Events
7 Day Returns
-7.5%
DB:PTNA
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-13.6%
DB:PTNA
-10.6%
DE Biotechs
-6.2%
DE Market
PTNA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Palatin Technologies (PTNA) -7.5% 6.8% 49.5% -13.6% 192.5% -0.2%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • PTNA underperformed the Biotechs industry which returned -10.6% over the past year.
  • PTNA underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
PTNA
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Palatin Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Palatin Technologies. This is due to cash flow or dividend data being unavailable. The share price is €0.9418.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Palatin Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Palatin Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PTNA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.00
AMEX:PTN Share Price ** AMEX (2019-04-18) in USD $1.06
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Palatin Technologies.

DB:PTNA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:PTN Share Price ÷ EPS (both in USD)

= 1.06 ÷ 0.00

625x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Palatin Technologies is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Palatin Technologies is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Palatin Technologies's expected growth come at a high price?
Raw Data
DB:PTNA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 625x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
63.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

DB:PTNA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 625x ÷ 63.3%

9.87x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Palatin Technologies is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Palatin Technologies's assets?
Raw Data
DB:PTNA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.10
AMEX:PTN Share Price * AMEX (2019-04-18) in USD $1.06
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:PTNA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:PTN Share Price ÷ Book Value per Share (both in USD)

= 1.06 ÷ 0.10

10.18x

* Primary Listing of Palatin Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Palatin Technologies is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Palatin Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Palatin Technologies has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Palatin Technologies expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
63.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Palatin Technologies expected to grow at an attractive rate?
  • Palatin Technologies's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Palatin Technologies's earnings growth is expected to exceed the Germany market average.
  • Palatin Technologies's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:PTNA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:PTNA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 63.3%
DB:PTNA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 32%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PTNA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PTNA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-06-30 86 50 44 1
2022-06-30 51 31 26 2
2021-06-30 63 19 41 2
2020-06-30 47 5 -4 3
2019-06-30 0 38 -24 2
DB:PTNA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 30 -8 0
2018-09-30 40 -5 8
2018-06-30 67 2 25
2018-03-31 80 -22 26
2017-12-31 82 29 23
2017-09-30 72 21 10
2017-06-30 45 13 -13
2017-03-31 11 12 -40
2016-12-31 -42 -49
2016-09-30 -45 -52
2016-06-30 -47 -52
2016-03-31 0 -43 -50

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Palatin Technologies's earnings are expected to grow significantly at over 20% yearly.
  • Palatin Technologies's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PTNA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Palatin Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PTNA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-06-30 0.20 0.20 0.20 1.00
2022-06-30 0.11 0.12 0.09 2.00
2021-06-30 0.15 0.24 0.06 2.00
2020-06-30 -0.02 -0.01 -0.03 2.00
2019-06-30 -0.11 -0.08 -0.13 2.00
DB:PTNA Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.00
2018-09-30 0.04
2018-06-30 0.12
2018-03-31 0.13
2017-12-31 0.12
2017-09-30 0.06
2017-06-30 -0.08
2017-03-31 -0.28
2016-12-31 -0.37
2016-09-30 -0.56
2016-06-30 -0.75
2016-03-31 -0.74

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Palatin Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Palatin Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Palatin Technologies has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Palatin Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Palatin Technologies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Palatin Technologies has delivered over 20% year on year earnings growth in the past 5 years.
  • Palatin Technologies's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Palatin Technologies's 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.
Earnings and Revenue History
Palatin Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Palatin Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PTNA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 29.62 0.34 9.60
2018-09-30 40.23 8.42 9.14
2018-06-30 67.13 24.70 8.64
2018-03-31 80.42 26.21 7.90
2017-12-31 82.28 23.38 10.26
2017-09-30 71.67 10.32 9.95
2017-06-30 44.72 -13.33 9.61
2017-03-31 10.82 -40.00 9.50
2016-12-31 -49.14 6.14
2016-09-30 -52.36 6.19
2016-06-30 -51.71 6.18
2016-03-31 0.00 -50.44 5.90
2015-12-31 0.00 -46.90 5.62
2015-09-30 8.02 -30.87 5.69
2015-06-30 12.95 -17.67 5.68
2015-03-31 12.95 -9.90 5.40
2014-12-31 12.95 -2.26 5.47
2014-09-30 4.93 -8.64 5.03
2014-06-30 -13.93 4.96
2014-03-31 0.00 -14.33 5.16 10.53
2013-12-31 0.00 -16.83 5.03 10.53
2013-09-30 0.01 -14.90 5.05 10.53
2013-06-30 0.01 -20.86 5.07
2013-03-31 0.02 -21.40 4.71
2012-12-31 0.05 -23.40 4.98
2012-09-30 0.05 -24.35 5.00
2012-06-30 0.07 -17.25 5.05 13.81

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Palatin Technologies has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Palatin Technologies used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Palatin Technologies has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Palatin Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Palatin Technologies has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Palatin Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Palatin Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Palatin Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Palatin Technologies has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Palatin Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 10.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Palatin Technologies Company Filings, last reported 3 months ago.

DB:PTNA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 21.14 2.32 24.66
2018-09-30 25.17 4.81 32.62
2018-06-30 26.96 6.28 38.00
2018-03-31 10.23 8.25 25.74
2017-12-31 9.63 10.21 34.96
2017-09-30 5.98 12.17 39.96
2017-06-30 -5.16 14.12 40.45
2017-03-31 -18.86 16.06 55.43
2016-12-31 -15.96 17.67 13.49
2016-09-30 -21.77 18.60 10.25
2016-06-30 -17.59 19.52 9.38
2016-03-31 -4.70 19.67 23.15
2015-12-31 7.48 19.63 33.37
2015-09-30 20.23 19.59 47.52
2015-06-30 12.20 9.85 27.30
2015-03-31 23.98 9.83 36.73
2014-12-31 32.68 9.81 42.69
2014-09-30 10.80 0.00 17.79
2014-06-30 9.79 0.00 12.18
2014-03-31 13.99 0.00 16.72
2013-12-31 15.26 0.01 18.18
2013-09-30 18.67 0.01 22.34
2013-06-30 22.98 0.02 24.42
2013-03-31 27.60 0.03 29.54
2012-12-31 31.46 0.03 32.85
2012-09-30 33.00 0.04 33.46
2012-06-30 1.83 0.04 3.83
  • Palatin Technologies's level of debt (11%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.1% vs 11% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Interest payments on debt are not well covered by earnings (EBIT is 2.3x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess Palatin Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Palatin Technologies has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Palatin Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Palatin Technologies dividends.
If you bought €2,000 of Palatin Technologies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Palatin Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Palatin Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PTNA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PTNA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-06-30
2022-06-30
2021-06-30
2020-06-30
2019-06-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Palatin Technologies has not reported any payouts.
  • Unable to verify if Palatin Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Palatin Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Palatin Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Palatin Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Palatin Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Palatin Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Palatin Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Carl Spana
COMPENSATION $3,215,939
AGE 56
TENURE AS CEO 18.8 years
CEO Bio

Dr. Carl Spana, Ph.D., is a Co-Founder of Palatin Technologies Inc and has been its Chief Executive Officer and President since June 14, 2000. From June 1996 to June 14, 2000, Dr. Spana served as an Chief Technical Officer and Executive Vice President of Palatin Technologies Inc. From June 1993 to June 1996, he served as Vice President of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm and of Castle Group Ltd., a medical venture capital firm. At Paramount Capital Investments and at Castle Group, Dr. Spana was responsible for discovering, evaluating and commercializing biotechnologies. Through his work at Paramount Capital Investments and Castle Group, he co-founded and acquired several private biotechnology firms. He served as AVAX Technologies, Inc.'s interim President from August 1995 to June 15, 1996. He served as an Chief Technology Officer and Executive Vice President of Rhomed Incorporated. From July 1991 to June 1993, he served as a Research Associate at Bristol-Myers Squibb, a publicly traded pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana’s qualifications for our board include his leadership experience, business judgment and industry experience. As a senior executive of Palatin for over nineteen years, he provides in-depth knowledge of Palatin Technologies, Inc. company's drug products under development and the competitive and corporate partnering landscape. Dr. Spana has been a Director of Palatin Technologies Inc. since June 1996 and Curalogic A/S since 2005. He has been a Director of RhoMed Incorporated, a wholly-owned subsidiary of Palatin Technologies Inc. since July 1995. Dr. Spana served as a Director of AVAX Technologies, Inc since September 1995. Dr. Spana received his Ph.D. in Molecular Biology from The Johns Hopkins University and his B.S. in Biochemistry from Rutgers University.

CEO Compensation
  • Carl's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
  • Carl's remuneration is higher than average for companies of similar size in Germany.
Management Team

John K. Prendergast

TITLE
Co-Founder & Non-Executive Chairman
COMPENSATION
$273K
AGE
64

Carl Spana

TITLE
Co-Founder
COMPENSATION
$3M
AGE
56
TENURE
18.8 yrs

Steve Wills

TITLE
CFO, COO
COMPENSATION
$3M
AGE
61
TENURE
21.4 yrs

Burns McClellan

TITLE
Vice President of Investor Relations
Board of Directors Tenure

Average tenure and age of the Palatin Technologies board of directors in years:

10.7
Average Tenure
64.5
Average Age
  • The average tenure for the Palatin Technologies board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Carl Spana

TITLE
Co-Founder
COMPENSATION
$3M
AGE
56
TENURE
22.8 yrs

Alan Dunton

TITLE
Director
COMPENSATION
$150K
AGE
64
TENURE
7.8 yrs

John K. Prendergast

TITLE
Co-Founder & Non-Executive Chairman
COMPENSATION
$273K
AGE
64
TENURE
18.8 yrs

Robert deVeer

TITLE
Director
COMPENSATION
$150K
AGE
72
TENURE
20.4 yrs

Raymond Rosen

TITLE
Member of Female Sexual Dysfunction Expert Panel

Michael Perelman

TITLE
Member of Female Sexual Dysfunction Expert Panel

J. Hull

TITLE
Director
COMPENSATION
$143K
AGE
66
TENURE
13.6 yrs

Angela Rossetti

TITLE
Director
COMPENSATION
$140K
AGE
65
TENURE
5.8 yrs

Arlene Morris

TITLE
Director
COMPENSATION
$140K
AGE
66
TENURE
3.8 yrs

Tony Manning

TITLE
Director
COMPENSATION
$143K
AGE
56
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
21. Nov 18 Buy Arlene Morris Individual 20. Nov 18 20. Nov 18 12,000 €0.60 €7,216
19. Nov 18 Buy Alan Dunton Individual 15. Nov 18 16. Nov 18 10,332 €0.70 €7,045
19. Nov 18 Buy Carl Spana Individual 16. Nov 18 16. Nov 18 20,000 €0.69 €13,825
19. Nov 18 Buy Stephen Wills Individual 16. Nov 18 16. Nov 18 20,000 €0.68 €13,465
X
Management checks
We assess Palatin Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Palatin Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL­3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Details
Name: Palatin Technologies, Inc.
PTNA
Exchange: DB
Founded: 1986
$191,397,840
203,063,429
Website: http://www.palatin.com
Address: Palatin Technologies, Inc.
Cedar Brook Corporate Center,
4B Cedar Brook Drive,
Cranbury,
New Jersey, 08512,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX PTN Common Stock NYSE MKT LLC US USD 28. Oct 1993
DB PTNA Common Stock Deutsche Boerse AG DE EUR 28. Oct 1993
LSE 0KF3 Common Stock London Stock Exchange GB USD 28. Oct 1993
Number of employees
Current staff
Staff numbers
19
Palatin Technologies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 20:53
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/02/11
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.